Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.57 |
| ▸ | BRAF | P15056 | 10/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | ARAF | P10398 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622554 | 0.93 | LCK (0.57) | LCKBRAFMAPK14KDRJAK3 | |
| SCHEMBL5622001 | 0.85 | LCK (0.69) | LCKBRAFMAPK14KDRRAF1 | |
| SCHEMBL5622270 | 0.84 | LCK (0.64) | LCKBRAFMAPK14KDRJAK3 | |
| SCHEMBL5622774 | 0.84 | LCK (0.59) | LCKBRAFMAPK14KDRRAF1 | |
| SCHEMBL4724615 | 0.82 | BRAF (0.66) | LCKBRAFKDRRAF1ARAF | |
| SCHEMBL4723069 | 0.82 | LCK (0.54) | LCKBRAFRAF1ARAF | |
| SCHEMBL374492 | 0.82 | LCK (0.70) | LCKBRAFMAPK14KDRRAF1 | |
| SCHEMBL4722460 | 0.80 | BRAF (0.54) | LCKBRAFMAPK14RAF1 | |
| SCHEMBL14572502 | 0.80 | BRAF (0.51) | LCKBRAFRAF1ARAF | |
| SCHEMBL4761727 | 0.80 | BRAF (0.57) | LCKBRAFRAF1ARAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | claimed |
| WO-2007024754-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | AMGEN INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | TIE1, KDR, BDKRB2 | LCK 376/4885BRAF 254/4885MAPK14 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.